Navigation Links
Cardiome to Release Third Quarter Results
Date:11/6/2009

NASDAQ: CRME TSX: COM

VANCOUVER, Nov. 6 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will report financial results for the third quarter ended September 30, 2009 on the morning of Monday, November 9, 2009. Cardiome will hold a teleconference call and webcast at 9:00am Eastern (6:00am Pacific) on that day to discuss the results.

To access the conference call, please dial 416-695-7806 or 888-789-9572 and reference conference 2345242. There will be a separate dial-in line for analysts on which we will respond to questions at the end of the call. The webcast can be accessed through Cardiome's website at www.cardiome.com.

Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through December 9, 2009. Please dial 416-695-5800 or 800-408-3053 and enter code 3147267 followed by the number sign to access the replay.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ National Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

SOURCE Cardiome Pharma Corp.


'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiome to Present at Bear Stearns Conference
2. Cardiome to Present at ThinkEquity Conference
3. Cardiome to Present at CIBC Conference
4. Cardiome To Release Third Quarter Results
5. Cardiome Initiates Phase 1 Study for GED-aPC
6. Cardiome Updates Guidance
7. Cardiome to Hold Investor Update Call
8. Cardiome And Astellas Announce Regulatory Update
9. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
10. Cardiome To Release 2007 Results
11. Cardiome To Release 2008 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... Dr. Elyson ... wisdom tooth removal surgery at their office. Wisdom tooth removal, a common dental procedure, ... always problematic, they often are improperly erupted, resulting in risks of complications. By providing ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... of foundational nutrients that supports cellular and metabolic health. This synergistic combination of ... mg free-form curcumin, along with 150 mg of reduced glutathione and 200 mg ...
(Date:5/4/2016)... ... May 04, 2016 , ... Francesca Loparco, Co-Founder of ... life forever with a same-day LASIK procedure at Christenbury Eye Center. The ... Jonathan Christenbury performed her surgery the same day as her in-office consultation and eye ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... industry, today announced that it was chosen as the Pharmaceutical News Provider of ... . The awards acknowledge the hard work and dedication of community members who ...
(Date:5/4/2016)... ... May 04, 2016 , ... Bayco ... compact tactical (6.7 inch) dual-light flashlights in models NSP-9842XL and NSR-9844XL . ... retail starting at $59.95) uses 2 included CR-123 batteries to produce up to ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... KANSAS CITY, Mo. , May 3, 2016 ... of Kansas Medical Center,s Institute for Advancing Medical ... develop and commercialize new drugs, diagnostics and medical ... organizations provides BioNovus Innovations with rights to license, ... "This partnership ...
(Date:5/3/2016)... -- As a teenager, an active and athletic Randy ... heart. He continued enjoying sports and recreation throughout his ... was giving out and he was a few hours ... Mesa, Arizona resident received a ... transplant, the SynCardia TAH-t is the only approved device ...
(Date:5/3/2016)...  While you may be familiar with watching a film or TV show in high definition, ... 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller of the medical industry,s ... - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
Breaking Medicine Technology: